Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07475546 · ClinicalTrials.gov registry record · Phase 3
Combination Gerotherapeutic Interventions for Healthspan Improvement
A Phase 3 study of Aging and Longevity, sponsored by AgelessRx.
- Active
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07475546: Active Phase 3 study of Aging and Longevity, sponsored by AgelessRx.
NCT07475546 is a Phase 3 study of Aging and Longevity that is active but no longer recruiting, run by AgelessRx. The registered enrollment target is 30 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07475546, a Phase 3 study of Aging and Longevity, is active but no longer recruiting, sponsored by AgelessRx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes. In this proof-of-concept phase, a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three arms: 1) Control, 2) Multi-therapy (B12, Naltrexone, Metformin, and NAD+), or 4) Comprehensive Therapy (Rapamycin, Naltrexone, Metformin, B12, NAD+, GSH, and Infinite Supplement).
Primary Outcome
Maximal oxygen uptake (VO₂ max) will be assessed using standardized cardiopulmonary exercise testing. This assessment will be conducted once at baseline and once at the 3-month follow-up. The outcome will be the change in VO₂ max from baseline to 3 months.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Rapamycin
- DRUG Naltrexone
- DRUG NAD+
- DRUG GSH
Study Locations (1)
Michigan
- AgelessRx - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
What the registry record for NCT07475546 still lists
NCT07475546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 5 interventions - of which Metformin is the first listed.
NCT07475546 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07475546 about?
NCT07475546 is a clinical study titled "Combination Gerotherapeutic Interventions for Healthspan Improvement". This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes. In this proof-of-concept phase, a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three ar...
What is the current status of trial NCT07475546?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2025-07-23. Estimated completion is 2026-04.
What conditions does trial NCT07475546 study?
This clinical trial studies the following conditions: Aging, Longevity, Healthspan Improvement.
What interventions are being tested in trial NCT07475546?
The interventions under investigation include: Metformin (DRUG), Rapamycin (DRUG), Naltrexone (DRUG), NAD+ (DRUG), GSH (DRUG).
Who is sponsoring clinical trial NCT07475546?
This trial is sponsored by AgelessRx, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07475546 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07475546's enrollment target sits among peer trials
30 193rd of 262 higher than 60 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SMART Exercise for PAD
RECRUITING · Phase 3
-
The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics
ACTIVE NOT RECRUITING · Phase 3
-
ACHIEVE Brain Health Follow-Up Study
ACTIVE NOT RECRUITING · Phase 3
-
SeniorWISE: Improving Everyday Memory in At-Risk Elderly
COMPLETED · Phase 3
-
Exercise, Executive Processes and the Aging Brain
COMPLETED · Phase 3
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI